Abstract The base excision repair protein, MUTYH, functionally interacts with the DNA mismatch repair (MMR) system. As genetic testing moves from testing one gene at a time, to gene panel and whole exome next generation sequencing approaches, understandin g the risk associated with co-existence of germline mutations in these genes will be important for clinical interpretation and management. From the Colon Cancer Family Registry, we identified 10 carriers who had both a MUTYH mutation (6 with c.1187G [A p.(Gly396Asp), 3 with c.821G [A p.(Arg274Gln), and 1 with c.536A [G p.(Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 375 carriers of a single (monoallelic) MUTYH mutation alone, and 469 carriers of a MMR gene mutation alone. Of the 10 carriers of both gene mutations, 8 were diagnosed with colorectal cancer. Using a weighted cohort analysis, we estimated that risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was substantially higher than that for carriers of a MUTYH mutation alone [hazard ratio ( 
Introduction
People with a heterozygous germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2, are at a substantially increased risk of colorectal cancer i.e. Lynch syndrome, previously known as hereditary non-polyposis colorectal cancer or HNPCC [1, 2] . People with a heterozygous germline mutation in the DNA base-excision repair gene MUTYH (monoallelic MUTYH mutation carriers) are at a small increased risk of colorectal cancer [3] [4] [5] [6] . As genetic testing advances from the iterative process of testing one gene at a time, to gene panel and whole exome next generation sequencing approaches in which multiple genes are tested simultaneously, understanding cancer risks associated with the coexistence of mutations within these genes is becoming increasingly important for appropriate clinical interpretation and management. Several studies have investigated potential genetic modifiers of cancer risks for MMR gene mutation carriers by examining the role of mutations in other genes and intergenic regions on their risk of colorectal cancer [7] [8] [9] [10] [11] [12] [13] [14] [15] . A protein-protein interaction between MSH6 and MUTYH in the oxidative DNA damage repair pathway has been reported by Gu et al. [16] . Some studies have observed that a mutation in MSH6 is more likely to be present in individuals with a MUTYH mutation who have colorectal cancer [17, 18] . Other studies, however, have observed no such associations [19] [20] [21] [22] [23] . In this study, we aimed to estimate the risk of colorectal cancer for carriers of both a MUTYH mutation and a MMR gene mutation compared with carriers of monoallelic MUTYH mutation alone and carriers of a MMR gene mutation alone.
Materials and methods

Study sample
The study comprised of carriers of a mutation in one or both of MUTYH and a MMR gene, from both populationand clinic-based families of the Colon Cancer Family Registry that is described in detail elsewhere [24] and at http://coloncfr.org. Between 1997 and 2012, the Colon Cancer Family Registry recruited families via: populationbased probands who were recently diagnosed colorectal cancer cases from state or regional population cancer registries in the USA (Washington, California, Arizona, Minnesota, Colorado, New Hampshire, North Carolina, and Hawaii), Australia (Victoria) and Canada (Ontario); and clinic-based probands who were enrolled from multiple-case families referred to family cancer clinics in the USA (Mayo Clinic, Rochester, Minnesota, and Cleveland Clinic, Cleveland, Ohio), Canada (Ontario), Australia (Melbourne, Adelaide, Perth, Brisbane, Sydney) and New Zealand (Auckland). Probands were asked for permission to contact their relatives to seek their enrolment in the Cancer Family Registry. For population-based families, first-degree relatives of probands were recruited and recruitment was extended to more distant relatives by some registries. For clinic-based families, recruitment was based on availability but attempts were made to recruit up to second-degree relatives of affected individuals (detailed in Newcomb et al. [24] ). Informed consent was obtained from all study participants, and the study protocol was approved by the institutional research ethics review board at each centre of the Colon Cancer Family Registry.
Data collection
Information of demographics, personal characteristics, personal and family history of cancer, cancer-screening history, history of polyps, polypectomy, and other surgeries was obtained by questionnaires from all probands and participating relatives. Participants were followed approximately every 5 years after baseline to update this information. The present study was based on all available baseline and follow-up data. Reported cancer diagnoses and age at diagnosis were confirmed using pathology reports, medical records, cancer registry reports, and death certificates, where possible. The tumor anatomic location and histology were coded and stored using the International Classification of Diseases for Oncology [25] . Blood samples from all participants and tumor tissue samples from all colorectal cancer-affected participants were obtained.
MMR gene mutation testing
Testing for germline mutations in MLH1, MSH2, MSH6, and PMS2 was performed for all population-based probands with a MMR-deficient colorectal tumor as evidenced by either high levels of tumor microsatellite instability (MSI-high) and/or loss of expression of one or more of the four MMR proteins by immunohistochemistry (IHC). Testing was undertaken for the youngest-onset colorectal cancer participant from each clinic-based family regardless of tumor microsatellite instability or MMR protein expression status. Testing for MLH1, MSH2 and MSH6 mutations was performed using Sanger sequencing or denaturing high performance liquid chromatography, followed by confirmatory DNA sequencing (reference sequences and exon numbering: for MLH1, NG_007109.2 and NM_000249.3; for MSH2, NG_007110.2 and NM_000 251.2; and for MSH6, NG_007111.1 and NM_000179.2). Large duplication and deletions including those involving EPCAM, which lead to MSH2 methylation, were detected by Multiplex Ligation Dependent Probe Amplification according to the manufacturer's instructions (MRC Holland, Amsterdam, The Netherlands) [24, 26, 27] . PMS2 mutations were identified using a modified protocol from Senter et al. [28] where exons 1-5, 9 and 11-15 were amplified in three long-range polymerase chain reactions (PCRs), followed by nested exon-specific PCR and sequencing. The remaining exons (6, 7, 8 and 10) were amplified and sequenced directly from genomic DNA. Large-scale deletions in PMS2 were detected using the P008-A1 MLPA kit according to manufacturer's specifications (MRC Holland, Amsterdam, The Netherlands) (reference sequence for PMS2, NG_008466.1 and NM_000535.5). The relatives of probands with a pathogenic MMR germline mutation, who provided a blood sample, underwent testing for the specific mutation identified in the proband.
MUTYH mutation testing
All probands were tested for MUTYH mutations. Genomic DNA extracted from each participant was tested at a central testing facility (Analytic Genetics Technology Center, Toronto, Canada) as previously described by Cleary et al. To confirm the MUTYH mutations and identify additional mutations, screening of the entire MUTYH coding region, promoter, and splice site regions was performed on all samples exhibiting MS mobility shifts using denaturing high-performance liquid chromatography (Transgenomic Wave 3500HT System; Transgenomic, Omaha, NE). All MS-detected mutations and WAVE mobility shifts were submitted for sequencing for mutation confirmation (ABI PRISM 3130XL Genetic Analyser). That is, if a monoallelic MUTYH mutation was identified, then the MUTYH gene was screened for any additional mutations not captured by the sequenom genotyping screen to ensure all potential compound heterozygous carriers were identified. The relatives of probands with a pathogenic MUTYH germline mutation, underwent testing for the specific mutation identified in the proband.
Statistical analysis
As a proportion of mutation carriers from this study were ascertained from multiple-case cancer families, and colorectal cancer cases were preferentially tested for a MUTYH or a MMR gene mutation, subject selection for testing genetic mutation was not random with respect to disease status. We adjusted for this non-random ascertainment by applying probability weights to carriers based on the approach described by Antoniou et al. [29] . A simulation study of the weighted cohort approach applied to Cox regression demonstrated that applying rates from an external reference population to adjust for the non-random ascertainment removed bias when the external rates were correctly specified and reduced bias even if the external rates were not completely accurate [29] .
Age-specific incidences of colorectal cancer for carriers were calculated by multiplying the age-specific population incidence by the hazard ratio (HR) of colorectal cancer for carriers of MUTYH [4] or MMR [30] gene mutations. Data of age-, sex-and country-specific population-based incidences of colorectal cancer in 1998 to 2002 for 5-year intervals was obtained for Australia, Canada, and USA [31] . These age-specific incidences of colorectal cancer for carriers were used to calculate sampling fractions to weigh the proportion of colorectal cancer-affected carriers and unaffected carriers in each age stratum so that the proportion of affected carriers in each age group was equal to the proportion in the general population.
Cox proportional hazard regressions with age as the time metric were used to estimate the risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation compared with carriers of a monoallelic MUTYH mutation alone and carriers of a MMR gene mutation alone. The time at risk for each carrier started at birth, and ended at: age at first diagnosis of colorectal cancer for carriers diagnosed with colorectal cancer; and age at first diagnosis of extracolonic cancer or last contact or death, whichever occurred the earliest, for carriers without colorectal cancer. Multivariable models were fitted after adjusting for sex and country of recruitment. HRs and robust estimates of corresponding 95 % confidence intervals (CIs) were calculated by taking into account clustering by family membership to allow for correlation of risk between relatives from the same family [32, 33] . Student's t-tests were used to compare estimated mean age at diagnosis of colorectal cancer between carriers of a mutation in single gene and carriers of a mutation in both genes. Fisher's exact tests were used to compare the frequency of carriers. All statistical tests were two-sided. All statistical analyses were performed using Stata 13.0 [34] .
Results
From the Colon Cancer Family Registry, we identified a total of 854 individuals (593 probands and 261 relatives) who were known to carry a mutation in one or both of MUTYH and a MMR gene. Of these, there were 469 carriers of a MMR gene mutation alone, 375 carriers of a monoallelic MUTYH mutation alone, and 10 carriers of both a monoallelic MUTYH mutation and a MMR gene mutation. Of the 375 carriers of a monoallelic MUTYH mutation alone, 76 were genotyped and confirmed as noncarriers of a MMR gene mutation, and the remainders were assumed to be non-carriers of a MMR gene mutation (details in Fig. 1) .
Of the 10 carriers of both a monoallelic MUTYH mutation Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 8 were diagnosed with colorectal cancer, of which 4 (50 %) were located in the sigmoid colon or rectum. For affected carriers of a monoallelic MUTYH mutation alone, 31 % of their tumors were in the proximal colon, 62 % in the distal colon or rectum, and 7 % in a non-specific site of the colon. For affected carriers of a MMR gene mutation alone, 58 % of their tumors were in the proximal colon, 34 % in the distal colon or rectum, and 8 % in a non-specific site of the colon ( Table 2 ). The mean age at diagnosis of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was 46.6 (standard deviation [SD] 14.0) years, which was not different from carriers of a monoallelic MUTYH mutation alone (mean 53.5, SD 12.1; p = 0.12) or carriers of a MMR gene mutation alone (mean 43.4, SD 10.6; p = 0.39). The majority of carriers of both a MUTYH and a MMR gene mutation (7 of 10) also developed extracolonic cancers in the small bowel, uterus, biliary tract, prostate and skin (Table 1) .
In the 385 monoallelic MUTYH mutation carriers (including the 10 who also carried a MMR gene mutation), the frequency of MMR gene mutations was higher in those with colorectal cancer (8/159, 5.0 %) compared with those without colorectal cancer (2/226, 0.9 %; p = 0.02). In the 479 MMR gene mutation carriers (including the 10 who also carried a MUTYH mutation), there was no evidence for a difference in the frequency of monoallelic MUTYH mutations between those with colorectal cancer (8/411, 2.0 %) and those without colorectal cancer (2/68, 2.9 %; p = 0.64) ( Table 2) .
Based on the weighted cohort analyses, the risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was 21.5-times (95 % CI 9.19-50.1; p \ 0.001) higher than for carriers of a monoallelic MUTYH mutation alone. A sensitivity analysis restricted to individuals with genotype data for both MUTYH and MMR gene mutations (n = 86) showed a very similar result to the main analysis (HR 14.5, 95 % CI 3.30-63.7; p \ 0.001). There was no statistical evidence of a difference in the risk of colorectal cancer between carriers of both a MUTYH and a MMR gene mutation and carriers of a MMR gene mutation alone (HR 1.94, 95 % CI 0.63-5.99; p = 0.25).
Discussion
As the MMR system functionally interacts with the base excision repair protein MUTYH [16] , we hypothesized that the combined effect of having a mutation in both a MUTYH gene and a MMR gene increases colorectal cancer risk compared with only carrying a single gene mutation. From identifying the 10 individuals with a germline mutation in both a MUTYH gene and a MMR gene, we found no evidence that a monoallelic MUTYH mutation confers additional risk of colorectal cancer for carriers of a MMR gene mutation.
We found that, for MMR gene mutation carriers, there was no difference in the frequency of monoallelic MUTYH mutations between those with colorectal cancer and those without colorectal cancer. This finding is consistent with other studies: Steinke et al. [19] found that the frequency of monoallelic MUTYH mutations in MSH6 mutation carriers with colorectal cancer (2/64, 3.1 %) was not significantly higher than that of controls (9/577, 1.6 %, p = 0.30); Ashton et al. [22] found that the frequency of MUTYH mutations in MLH1 and MSH2 mutation carriers (2/209, 1 %) was not higher than that of controls (4/296, 1.35 %; p = 0.69); van Puijenbroek et al. [21] found no evidence of a combined effect of heterozygous MSH6 and MUTYH mutations, except perhaps for urothelial tumors; and Gorgens et al. [23] found only one monoallelic MUTYH mutation of c.1187G[A p.(Gly396Asp) in 50 individuals with suspected HNPCC compared with no MUTYH mutation in 116 controls. Further, Stormorken et al. [20] reported that frequency of monoallelic MUTYH mutations in individuals with HNPCC, HNPCC-like or dominantly inherited late-onset colorectal cancer (2/96, 2 %) was not more than expected by chance, and concluded that monoallelic MUTYH mutations may not increase risk of cancer in these individuals.
In contrast with our finding, Niessen et al. [18] found an over-representation of monoallelic MUTYH mutations in colorectal or endometrial cancer cases with a MSH6 missense mutation (4/20, 20 %) compared with colorectal cancer cases without a MMR mutation (1/134, 0.7 %; p = 0.002) and controls (1.5 %, p = 0.001). This finding, however, might be attributable to indiscriminate MMR testing of all individuals despite the appearance of normal tumor IHC staining for MSH6 and low frequency MSI (MSI-low) whereas our study only performed MMR genetic testing of population-based probands with tumor tissue that was MSI-high or showed loss of MMR protein expression by IHC testing. It is possible, due to our testing regimen, that our findings are confined to MMR gene mutations that are at the higher end of pathogenicity, compared with the study of Niessen et al. [18] .
We found that the risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was significantly higher than for carriers of a monoallelic MUTYH mutation alone. This finding is likely to be a reflection of the substantially increased risk of colorectal cancer due to a MMR gene mutation [35] , and a small increased risk due to a monoallelic MUTYH mutation [4] . That is, a monoallelic MUTYH mutation might not modify the risk of colorectal cancer for carriers of a MMR gene mutation. In this study, we found that the frequency of MMR gene mutations was higher in monoallelic MUTYH mutation carriers with colorectal cancer than those without colorectal cancer. This is consistent with the finding by Giráldez et al. [17] that MSH6 mutations were more frequent in MUTYH mutation carriers than non-carriers (3/26 = 11.5 % vs. 0/50 = 0 %, p = 0.04). However, we did not observe any individuals with a MSH6 mutation among the monoallelic MUTYH mutation carriers in this study.
Previous studies have reported that MMR gene mutation-associated colorectal cancers [36] and those attributed to biallelic mutations in MUTYH [6, 37] are more likely to
MUTYH+ ( be diagnosed in the proximal colon. We found an apparently different distribution of tumor location for carriers of both a MUTYH and a MMR gene mutation given that about half of colorectal cancers in these mutation carriers were located in the sigmoid colon or rectum. However, we cannot make a conclusion on colorectal tumor location distribution as well as extracolonic cancer distribution for carriers of both a MUTYH and a MMR gene mutation because of the small number of cases. Individuals who carried both biallelic MUTYH mutations and a MMR gene mutation were not observed in our study, consistent with previous reports [19] [20] [21] [22] [23] 38] . In this study, risk estimates were adjusted for possible selection bias by application of appropriate weights to minimise bias when participants are selected on the basis of phenotype [29] . Additionally, standardized epidemiologic assessments and uniformly high-quality testing for gene mutations were used across all Colon Cancer Family Registry centers [24] . A major limitation of the study is that we were not able to sequence the MMR genes for all MUTYH mutation carriers regardless of tumor phenotype (tumor mismatch repair status) in the Colon Cancer Family Registry. However, a sensitivity analysis using individuals with genotype data for both MUTYH and MMR gene mutations showed a very similar result to the main analysis. Another limitation is that there is a possibility of survival bias since cases with poor survival were unable to participate in the study as they would not have been able to provide a blood sample for genetic testing. Since we preferentially included individuals with a pathogenic MMR gene mutation that are likely to cause colorectal cancer especially colorectal cancer with tumor MMR deficiency, then our findings are relevant to individuals with a MMR gene mutation likely to cause colorectal cancer, which we would argue, are more likely relevant to family cancer clinics.
Within the limited power of this study, we observed no differences in the risk of colorectal cancer for MMR gene mutation carriers who also carry a MUTYH mutation. In contrast, there is a substantially high risk of colorectal cancer for MUTYH mutation carriers who also carry a MMR gene mutation. Our data suggest that for MMR gene mutation carriers there is no advantage to the carrier, with respect to their screening recommendations, for having additional testing for MUTYH. However, for monoallelic MUTYH mutation carriers, additional testing for MMR germline mutations (if their tumor shows MMR deficiency) is warranted as co-existence of a pathogenic MMR gene mutation would result in recommendations for increased screening.
